These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34292372)

  • 21. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL.
    Yao CC; Hung CH; Hu TH; Lu SN; Wang JH; Lee CM; Chen CH
    Sci Rep; 2017 May; 7(1):1839. PubMed ID: 28500322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive Value of HBsAg for Off-treatment Response in HBeAg-negative Chronic Hepatitis B Patients.
    Fan X; Li T; Liu F; Zhang L; Yang B; Wang L
    J Coll Physicians Surg Pak; 2023 Jan; 33(1):47-52. PubMed ID: 36597235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B.
    Lee IC; Sun CK; Su CW; Wang YJ; Chang HC; Huang HC; Lee KC; Huang YS; Perng CL; Liu YH; Chua CS; Lin YM; Lin HC; Huang YH
    Medicine (Baltimore); 2015 Aug; 94(32):e1341. PubMed ID: 26266383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients.
    Chen CH; Hsu YC; Lu SN; Hung CH; Wang JH; Lee CM; Hu TH
    J Viral Hepat; 2018 May; 25(5):590-597. PubMed ID: 29274189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
    Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
    J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcome after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients who achieved HBsAg seroclearance.
    Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Saitoh S; Arase Y; Kobayashi M; Kumada H
    J Gastroenterol; 2024 Jan; 59(1):34-44. PubMed ID: 37837569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B.
    Mak LY; Wong D; Kuchta A; Hilfiker M; Hamilton A; Chow N; Mao X; Seto WK; Yuen MF
    Clin Mol Hepatol; 2023 Jan; 29(1):146-162. PubMed ID: 35989092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation.
    Tsai YN; Wu JL; Tseng CH; Chen TH; Wu YL; Chen CC; Fang YJ; Yang TH; Nguyen MH; Lin JT; Hsu YC
    Clin Mol Hepatol; 2024 Jan; 30(1):98-108. PubMed ID: 38092551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low anti-HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen-negative patients.
    Ohlendorf V; Wübbolding M; Gineste P; Höner Zu Siederdissen C; Bremer B; Wedemeyer H; Cornberg M; Maasoumy B
    Liver Int; 2022 Dec; 42(12):2674-2682. PubMed ID: 36152268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
    Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion.
    Yao CC; Lee CM; Hung CH; Wang JH; Hu TH; Lu SN; Changchien CS; Hsu MC; Chen CH
    J Gastroenterol Hepatol; 2015 May; 30(5):918-24. PubMed ID: 25532588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B.
    Chi H; Hansen BE; Yim C; Arends P; Abu-Amara M; van der Eijk AA; Feld JJ; de Knegt RJ; Wong DK; Janssen HL
    Aliment Pharmacol Ther; 2015 May; 41(9):867-76. PubMed ID: 25752878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues.
    Wang Y; Liao H; Deng Z; Liu Y; Bian D; Ren Y; Yu G; Jiang Y; Bai L; Liu S; Liu M; Zhou L; Chen Y; Duan Z; Lu F; Zheng S
    J Viral Hepat; 2022 Jun; 29(6):420-431. PubMed ID: 35274400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients.
    Brakenhoff SM; de Knegt RJ; van Campenhout MJH; van der Eijk AA; Brouwer WP; van Bömmel F; Boonstra A; Hansen BE; Berg T; Janssen HLA; de Man RA; Sonneveld MJ
    J Microbiol Immunol Infect; 2023 Feb; 56(1):31-39. PubMed ID: 35941076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum HBV RNA is associated with liver fibrosis regression in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues.
    Bian D; Zhao J; Liao H; Wang Y; Ren Y; Jiang Y; Liu S; Chen X; Hu Z; Duan Z; Lu F; Zheng S
    J Viral Hepat; 2023 Apr; 30(4):303-309. PubMed ID: 36533536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative hepatitis B surface antigen titres in Chinese chronic hepatitis B patients over 4 years of entecavir treatment.
    Chen EQ; Wang TT; Bai L; Tao CM; Liang T; Liu C; Liao J; Tang H
    Antivir Ther; 2013; 18(8):955-65. PubMed ID: 23639885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Off-therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg-negative patients.
    Jeng WJ; Chang ML; Liaw YF
    J Viral Hepat; 2019 Aug; 26(8):1019-1026. PubMed ID: 31009126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 96-week clinical outcomes after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients.
    Xu WX; Li YM; Li JG; Mei YY; Chen YM; Li XJ; Lin CS; Deng H; Zhao ZX; Xie DY; Gao ZL; Peng L
    Gastroenterol Rep (Oxf); 2021 Aug; 9(4):313-322. PubMed ID: 34567563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
    Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
    Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
    Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.